Stefano Indraccolo

List of Publications by Year
in descending order

186	7,386	53794	69250
papers	citations	45 h-index	77 g-index

189	189	189	12877
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tumor-Targeted Interferon-Î± Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis. Cancer Cell, 2008, 14, 299-311.	16.8	267
2	Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget, 2014, 5, 4305-4319.	1.8	249
3	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2019, 20, 110-119.	10.7	238
4	Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell, 2013, 24, 766-776.	16.8	220
5	Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood, 2011, 117, 7053-7062.	1.4	199
6	Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood, 2004, 104, 92-99.	1.4	181
7	Retroviral Vectors for High-Level Transgene Expression in T Lymphocytes. Human Gene Therapy, 2003, 14, 1155-1168.	2.7	171
8	Identification of Genes Selectively Regulated by IFNs in Endothelial Cells. Journal of Immunology, 2007, 178, 1122-1135.	0.8	152
9	Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia. Leukemia, 2014, 28, 2324-2335.	7.2	147
10	Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology, 2013, 58, 1042-1053.	7.3	139
11	Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Nonâ€“Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clinical Cancer Research, 2019, 25, 7312-7319.	7.0	139
12	BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1Î± stability and MGMT expression. Cell Death and Disease, 2012, 3, e412-e412.	6.3	132
13	Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2014, 20, 4647-4659.	7.0	130
14	Cross-talk between Tumor and Endothelial Cells Involving the Notch3-Dll4 Interaction Marks Escape from Tumor Dormancy. Cancer Research, 2009, 69, 1314-1323.	0.9	124
15	M30 Neoepitope Expression in Epithelial Cancer: Quantification of Apoptosis in Circulating Tumor Cells by CellSearch Analysis. Clinical Cancer Research, 2010, 16, 5233-5243.	7.0	124
16	The Side Population of Ovarian Cancer Cells Is a Primary Target of IFN-Î± Antitumor Effects. Cancer Research, 2008, 68, 5658-5668.	0.9	121
17	Linking metabolic reprogramming to therapy resistance in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 1-6.	7.4	117
18	Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4216-4221.	7.1	113

#	Article	IF	Citations
19	Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. Journal of Hepatology, 2019, 70, 700-709.	3.7	112
20	Side population and cancer stem cells: Therapeutic implications. Cancer Letters, 2010, 288, 1-9.	7.2	109
21	Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia, 2014, 28, 278-288.	7.2	108
22	Hypoxia and HIF1Î± Repress the Differentiative Effects of BMPs in High-Grade Glioma. Stem Cells, 2009, 27, 7-17.	3.2	100
23	Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. Cell Reports, 2016, 15, 1134-1143.	6.4	96
24	Wnt activation promotes neuronal differentiation of Glioblastoma. Cell Death and Disease, 2013, 4, e500-e500.	6.3	89
25	Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology, 2011, 54, 890-899.	7.3	82
26	Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. Cancer Treatment Reviews, 2020, 87, 102031.	7.7	82
27	Absence of Neurofibromin Induces an Oncogenic Metabolic Switch via Mitochondrial ERK-Mediated Phosphorylation of the Chaperone TRAP1. Cell Reports, 2017, 18, 659-672.	6.4	81
28	LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-16.	4.0	78
29	Notch3 signalling promotes tumour growth in colorectal cancer. Journal of Pathology, 2011, 224, 448-460.	4.5	77
30	Interferon-Î± as angiogenesis inhibitor: Learning from tumor models. Autoimmunity, 2010, 43, 244-247.	2.6	75
31	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. Journal of Thoracic Oncology, 2018, 13, 1692-1704.	1.1	74
32	Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma. Clinical Cancer Research, 2019, 25, 1828-1837.	7.0	72
33	SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia. Leukemia, 2021, 35, 377-388.	7.2	68
34	Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization. Cancer Research, 2011, 71, 4214-4225.	0.9	67
35	PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review. Critical Reviews in Oncology/Hematology, 2019, 135, 128-134.	4.4	66
36	18F-FDG PET/CT in non-small-cell lung cancer patients. Nuclear Medicine Communications, 2019, 40, 802-807.	1.1	63

#	Article	IF	Citations
37	Anti-angiogenic gene therapy of cancer: Current status and future prospects. Molecular Aspects of Medicine, 2007, 28, 87-114.	6.4	62
38	VEGF-Targeted Therapy Stably Modulates the Glycolytic Phenotype of Tumor Cells. Cancer Research, 2015, 75, 120-133.	0.9	62
39	Precision medicine in cholangiocarcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 40-40.	3.0	61
40	RNA interference: Implications for cancer treatment. Molecular Aspects of Medicine, 2007, 28, 143-166.	6.4	60
41	The Angiogenic Switch: Implications in the Regulation of Tumor Dormancy. Current Molecular Medicine, 2009, 9, 935-941.	1.3	58
42	NOTCH3 Signaling Regulates MUSASHI-1 Expression in Metastatic Colorectal Cancer Cells. Cancer Research, 2014, 74, 2106-2118.	0.9	56
43	Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood, 2017, 130, 2750-2761.	1.4	54
44	Long Pentraxin-3 Inhibits FGF8b-Dependent Angiogenesis and Growth of Steroid Hormoneâ€“Regulated Tumors. Molecular Cancer Therapeutics, 2011, 10, 1600-1610.	4.1	53
45	Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy. Apmis, 2008, 116, 648-659.	2.0	52
46	A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. Neuro-Oncology, 2021, 23, 264-276.	1.2	48
47	Antiangiogenic Therapy Against Experimental Glioblastoma Using Genetically Engineered Cells Producing Interferon-Ì±, Angiostatin, or Endostatin. Human Gene Therapy, 2003, 14, 883-895.	2.7	46
48	Dormant Tumors Awaken by a Short-Term Angiogenic Burst: The Spike Hypothesis. Cell Cycle, 2006, 5, 1751-1755.	2.6	46
49	Therapeutic concentrations of digitoxin inhibit endothelial focal adhesion kinase and angiogenesis induced by different growth factors. British Journal of Pharmacology, 2017, 174, 3094-3106.	5.4	46
50	Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors. Scientific Reports, 2017, 7, 13936.	3.3	45
51	Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Research, 2016, 76, 4775-4784.	0.9	44
52	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Nonâ€“Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. Clinical Cancer Research, 2017, 23, 3316-3324.	7.0	43
53	Differential Regulation of Hypoxia-Induced CXCR4 Triggering during B-Cell Development and Lymphomagenesis. Cancer Research, 2007, 67, 8605-8614.	0.9	41
54	Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. British Journal of Cancer, 2014, 111, 25-32.	6.4	41

#	Article	IF	Citations
55	Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia. Journal of Leukocyte Biology, 2016, 99, 1077-1087.	3.3	41
56	Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. Cancers, 2020, 12, 2283.	3.7	41
57	Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Research, 2002, 62, 6099-107.	0.9	41
58	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. Critical Reviews in Oncology/Hematology, 2017, 119, 30-39.	4.4	40
59	Hypoxia Inducible Factor-1Î± Inactivation Unveils a Link between Tumor Cell Metabolism and Hypoxia-Induced Cell Death. American Journal of Pathology, 2008, 173, 1186-1201.	3.8	39
60	LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer. International Journal of Molecular Sciences, 2019, 20, 1874.	4.1	39
61	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood, 2005, 105, 931-939.	1.4	38
62	Inhibition of Tumor Angiogenesis by Angiostatin: From Recombinant Protein to Gene Therapy. Endothelium: Journal of Endothelial Cell Research, 2002, 9, 3-10.	1.7	37
63	Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. British Journal of Cancer, 2022, 127, 383-393.	6.4	36
64	Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983954.	3.2	35
65	Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer. British Journal of Cancer, 2020, 123, 81-91.	6.4	35
66	Interferon-Î± Gene Therapy by Lentiviral Vectors Contrasts Ovarian Cancer Growth Through Angiogenesis Inhibition. Human Gene Therapy, 2005, 16, 957-970.	2.7	34
67	hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: Implications for EBV-driven lymphomagenesis. International Journal of Cancer, 2007, 121, 576-587.	5.1	33
68	Interferon-Î± counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis, 2009, 30, 851-860.	2.8	33
69	Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts. FEBS Journal, 2012, 279, 882-891.	4.7	33
70	DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice. Carcinogenesis, 2015, 36, 115-121.	2.8	33
71	STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876374.	3.2	30
72	LKB1 loss is associated with glutathione deficiency under oxidative stress and sensitivity of cancer cells to cytotoxic drugs and Î³-irradiation. Biochemical Pharmacology, 2018, 156, 479-490.	4.4	30

#	Article	IF	Citations
73	Mutator Phenotype in Human Hematopoietic Neoplasms and Its Association With Deletions Disabling DNA Repair Genes and bcl-2 Rearrangements. Blood, 1999, 94, 2424-2432.	1.4	29
74	Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells. Oncotarget, 2017, 8, 6433-6445.	1.8	29
75	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. Translational Lung Cancer Research, 2021, 10, 202-220.	2.8	29
76	A CD3+CD8+ T Cell Population Lacking CD5 Antigen Expression Is Expanded in Peripheral Blood of Human Immunodeficiency Virus-Infected Patients. Clinical Immunology and Immunopathology, 1995, 77, 253-261.	2.0	28
77	Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. Blood, 2001, 98, 3607-3617.	1.4	28
78	Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 â˜’/â˜’ epithelial ovarian cancers. European Journal of Cancer, 2006, 42, 1475-1483.	2.8	28
79	Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus. Cell Death and Disease, 2015, 6, e1774-e1774.	6.3	28
80	Biochemical and genetic defects underlying human congenital hypotransferrinemia. The Hematology Journal, 2000, 1, 390-398.	1.4	28
81	hTERT Inhibition Triggers Epsteinâ€“Barr Virus Lytic Cycle and Apoptosis in Immortalized and Transformed B Cells: A Basis for New Therapies. Clinical Cancer Research, 2013, 19, 2036-2047.	7.0	27
82	Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells. Oncogene, 2018, 37, 3839-3851.	5.9	26
83	B cell activation and human immunodeficiency virus infection. V. Phenotypic and functional alterations in CD5+ and CD5? B cell subsets. Journal of Clinical Immunology, 1993, 13, 381-388.	3.8	25
84	Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: Microarray gene expression analyses. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 591, 198-211.	1.0	25
85	Rewiring of Lipid Metabolism and Storage in Ovarian Cancer Cells after Anti-VEGF Therapy. Cells, 2019, 8, 1601.	4.1	25
86	First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist, 2022, 27, 87-e115.	3.7	25
87	Recruitment of human umbilical vein endothelial cells and human primary fibroblasts into experimental tumors growing in SCID mice. Experimental Cell Research, 2003, 287, 28-38.	2.6	24
88	Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epsteinâ€“Barr virus-immortalized B cells. Experimental Cell Research, 2004, 295, 539-548.	2.6	23
89	Selective killing of human T-ALL cells: an integrated approach targeting redox homeostasis and the OMA1/OPA1 axis. Cell Death and Disease, 2018, 9, 822.	6.3	23
90	Undermining Tumor Angiogenesis by Gene Therapy: An Emerging Field. Current Gene Therapy, 2004, 4, 297-308.	2.0	23

#	Article	IF	Citations
91	DNA Immunization of Mice against SIVmac239 Gag and Env Using Rev-Independent Expression Plasmids. AIDS Research and Human Retroviruses, 1998, 14, 83-90.	1.1	22
92	Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer. BMC Cancer, 2019, 19, 821.	2.6	22
93	Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures. Nature Communications, 2021, 12, 2507.	12.8	22
94	Encapsulated cells producing retroviral vectors forin vivogene transfer. Journal of Gene Medicine, 2002, 4, 150-160.	2.8	21
95	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2018, 18, 1021-1030.	2.4	21
96	Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience. Oncologist, 2020, 25, e1996-e2005.	3.7	21
97	ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia. Oncotarget, 2017, 8, 26129-26141.	1.8	21
98	Frequency of a Mutated CCR-5 Allele (Delta32) among Italian Healthy Donors and Individuals at Risk of Parenteral HIV Infection. AIDS Research and Human Retroviruses, 1999, 15, 337-344.	1.1	20
99	Vandetanib Improves Anti-Tumor Effects of L19mTNFÎ± in Xenograft Models of Esophageal Cancer. Clinical Cancer Research, 2011, 17, 447-458.	7.0	20
100	Metabolic effects of antiangiogenic drugs in tumors: Therapeutic implications. Biochemical Pharmacology, 2014, 89, 162-170.	4.4	20
101	Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. Clinical Cancer Research, 2020, 26, 4478-4484.	7.0	20
102	Alternatively spliced forms of IgÎ± and IgÎ² prevent B cell receptor expression on the cell surface. European Journal of Immunology, 2002, 32, 1530.	2.9	19
103	Gene therapy of ovarian cancer with IFN-Î±-producing fibroblasts: comparison of constitutive and inducible vectors. Gene Therapy, 2006, 13, 953-965.	4.5	19
104	Efficacy Assessment of Interferon-Alphaâ€“Engineered Mesenchymal Stromal Cells in a Mouse Plasmacytoma Model. Stem Cells and Development, 2011, 20, 709-719.	2.1	19
105	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Nonâ€“small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clinical Lung Cancer, 2020, 21, 1-14.e3.	2.6	19
106	Angiogenesis meets immunology: Cytokine gene therapy of cancer. Molecular Aspects of Medicine, 2007, 28, 59-86.	6.4	18
107	Antineoplastic activity of lentiviral vectors expressing interferon-Î± in a preclinical model of primary effusion lymphoma. Blood, 2009, 113, 4525-4533.	1.4	18
108	Insights into the Regulation of Tumor Dormancy by Angiogenesis in Experimental Tumors. Advances in Experimental Medicine and Biology, 2013, 734, 37-52.	1.6	18

#	Article	IF	Citations
109	Impact of VEGFâ€dependent tumour microâ€environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice. Journal of Pathology, 2009, 219, 455-462.	4.5	17
110	The hu-PBL-SCID mouse in human lymphocyte function and lymphomagenesis studies: achievements and caveats. Seminars in Immunology, 1996, 8, 249-254.	5.6	16
111	Ligand-driven activation of the Notch pathway in T-all and solid tumors: Why Not(ch)?. Cell Cycle, 2010, 9, 80-85.	2.6	16
112	Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs. Clinical and Experimental Metastasis, 2010, 27, 419-439.	3.3	15
113	An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts. Cell Death and Disease, 2016, 7, e2047-e2047.	6.3	15
114	Calcineurin and GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor of apoptosis protein degradation. Leukemia, 2016, 30, 812-822.	7.2	15
115	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. Oncotarget, 2016, 7, 72654-72661.	1.8	15
116	A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model. Oncotarget, 2016, 7, 33081-33095.	1.8	15
117	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. Oncotarget, 2017, 8, 32626-32638.	1.8	14
118	mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells. Redox Biology, 2022, 51, 102268.	9.0	14
119	Standardization of in vitro synthesis and detection of HIV-1-specific antibodies. Journal of Immunological Methods, 1993, 157, 105-115.	1.4	13
120	TCR Expression and Clonality Analysis in Peripheral Blood and Lymph Nodes of HIV-Infected Patients. Human Immunology, 1997, 57, 93-103.	2.4	13
121	EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition. BMC Cancer, 2015, 15, 855.	2.6	13
122	Metformin: a modulator of bevacizumab activity in cancer? A case report. Cancer Biology and Therapy, 2015, 16, 210-214.	3.4	13
123	BBIT20 inhibits homologous DNA repair with disruption of the BRCA1â€“BARD1 interaction in breast and ovarian cancer. British Journal of Pharmacology, 2021, 178, 3627-3647.	5.4	13
124	Metabolic effects of anti-angiogenic therapy in tumors. Biochimie, 2012, 94, 925-931.	2.6	12
125	Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients. International Journal of Molecular Sciences, 2020, 21, 66.	4.1	12
126	Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice. Critical Reviews in Oncology/Hematology, 2021, 163, 103378.	4.4	12

#	Article	IF	Citations
127	Expression from cell type-specific enhancer-modified retroviral vectors after transduction: influence of marker gene stability. Gene, 2002, 283, 199-208.	2.2	11
128	Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line. British Journal of Haematology, 2005, 130, 878-889.	2.5	11
129	Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system. Cellular Oncology (Dordrecht), 2015, 38, 377-385.	4.4	11
130	Metabolism in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1263, 1-11.	1.6	11
131	A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia. Blood, 2021, 138, 1317-1330.	1.4	11
132	Modulation of Moloney Leukemia Virus Long Terminal Repeat Transcriptional Activity by the Murine CD4 Silencer in Retroviral Vectors. Virology, 2000, 276, 83-92.	2.4	10
133	Involvement of NADPH Oxidase 1 in Liver Kinase B1-Mediated Effects on Tumor Angiogenesis and Growth. Frontiers in Oncology, 2018, 8, 195.	2.8	10
134	Comparison of the Genomic Profile of Cancer Stem Cells and Their Non-Stem Counterpart: The Case of Ovarian Cancer. Journal of Clinical Medicine, 2020, 9, 368.	2.4	10
135	Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2020, 10, 607840.	2.8	10
136	Dominance of a single Epstein-Barr virus strain in SCID-mouse tumors induced by injection of peripheral blood mononuclear cells from healthy human donors. Virus Research, 1995, 36, 215-231.	2.2	9
137	Dissecting molecular mechanisms of resistance to NOTCH1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts. Haematologica, 2020, 105, 1317-1328.	3.5	9
138	Genetic Perturbation of Pyruvate Dehydrogenase Kinase 1 Modulates Growth, Angiogenesis and Metabolic Pathways in Ovarian Cancer Xenografts. Cells, 2021, 10, 325.	4.1	9
139	In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer. Frontiers in Oncology, 2016, 6, 164.	2.8	8
140	Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. Lung Cancer, 2016, 96, 52-55.	2.0	8
141	In situ Metabolic Profiling of Ovarian Cancer Tumor Xenografts: A Digital Pathology Approach. Frontiers in Oncology, 2020, 10, 1277.	2.8	8
142	ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis. Frontiers in Oncology, 2021, 11, 625636.	2.8	8
143	Analysis of Epsteinâ€“Barr virus (EBV) type and variant in spontaneous lymphoblastoid cells and Hu-SCID mouse tumours. Molecular and Cellular Probes, 1996, 10, 453-461.	2.1	7
144	Genetic variability of the human CD4 V2 domain. Immunogenetics, 1996, 44, 70-72.	2.4	7

#	Article	IF	Citations
145	A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients. Diagnostics, 2020, 10, 765.	2.6	7
146	Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment. International Journal of Molecular Sciences, 2020, 21, 1601.	4.1	7
147	Low P66shc with High SerpinB3 Levels Favors Necroptosis and Better Survival in Hepatocellular Carcinoma. Biology, 2021, 10, 363.	2.8	7
148	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. Future Oncology, 2021, 17, 2513-2527.	2.4	7
149	Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) Patients. Diagnostics, 2021, 11, 1468.	2.6	7
150	Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. Journal of Immunological Methods, 2004, 291, 153-163.	1.4	6
151	Genetic perturbation of IFN-Î± transcriptional modulators in human endothelial cells uncovers pivotal regulators of angiogenesis. Computational and Structural Biotechnology Journal, 2020, 18, 3977-3986.	4.1	6
152	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers, 2020, 12, 1303.	3.7	6
153	Potential of Induced Metabolic Bioluminescence Imaging to Uncover Metabolic Effects of Antiangiogenic Therapy in Tumors. Frontiers in Oncology, 2016, 6, 15.	2.8	5
154	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). Oncologist, 2019, 24, e318-e326.	3.7	5
155	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. Journal of Clinical Oncology, 2018, 36, 2047-2047.	1.6	4
156	Identification of a human endogenous LTR-like sequence using HIV-1 LTR specific primers. Molecular and Cellular Probes, 1996, 10, 443-451.	2.1	3
157	Reconstruction of gene regulatory modules from RNA silencing of IFN-Î± modulators: experimental set-up and inference method. BMC Genomics, 2016, 17, 228.	2.8	3
158	Evolving use of liquid biopsy in non-small-cell-lung cancer patients. International Journal of Biological Markers, 2020, 35, 23-25.	1.8	3
159	Filling the gap between risk assessment and molecular determinants of tumor onset. Carcinogenesis, 2021, 42, 507-516.	2.8	3
160	Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. Theranostics, 2021, 11, 1594-1608.	10.0	3
161	REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS).. Journal of Clinical Oncology, 2017, 35, TPS2085-TPS2085.	1.6	3
162	Vascular endothelial growth factor blockade elicits a stable metabolic shift in tumor cells: therapeutic implications. Molecular and Cellular Oncology, 2016, 3, e1008307.	0.7	2

#	Article	IF	Citations
163	LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. ESMO Open, 2020, 5, e000748.	4.5	2
164	Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients (PTS) with mismatch repair deficiency (MMRd): An observational study.. Journal of Clinical Oncology, 2019, 37, 2043-2043.	1.6	2
165	Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases. Translational Lung Cancer Research, 2019, 8, S435-S438.	2.8	2
166	Uncovering Metabolic Effects of Anti-angiogenic Therapy in Tumors by Induced Metabolic Bioluminescence Imaging. Methods in Molecular Biology, 2016, 1464, 175-184.	0.9	2
167	Concluding remarks. Molecular Aspects of Medicine, 2007, 28, 167.	6.4	1
168	Genes in the cure of cancer. Molecular Aspects of Medicine, 2007, 28, 1-3.	6.4	1
169	77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC). Journal of Thoracic Oncology, 2016, 11, S88.	1.1	1
170	Editorial on â€œThe AvaALL Randomized Clinical Trialâ€• Journal of Thoracic Disease, 2019, 11, S1237-S1240.	1.4	1
171	The Nucleotide Kinase Nadk Is Required for ROS Detoxification and Constitutes a Metabolic Vulnerability of NOTCH1-Driven T-ALL. Blood, 2018, 132, 2615-2615.	1.4	1
172	Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World. Frontiers in Oncology, 0, 12, .	2.8	1
173	The Isomerization Plant at Rosneft' Oil Companyâ€“Komsomol'sk Oil Refinery Open Joint-stock Company. Chemistry and Technology of Fuels and Oils, 2002, 38, 287-292.	0.5	0
174	Signaling Pathways in Cancer Stem Cells: Therapeutic Implications. , 2012, , 3-11.		0
175	166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series. Journal of Thoracic Oncology, 2016, 11, S130.	1.1	0
176	28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS). Journal of Thoracic Oncology, 2016, 11, S67.	1.1	0
177	Interferon- Gene Therapy by Lentiviral Vectors Contrasts Ovarian Cancer Growth Through Angiogenesis Inhibition. Human Gene Therapy, 2005, .	2.7	0
178	ZNF521 Is a Zinc Finger Protein That Prevents Differentiation Of Human MLL-AF9-Positive Myeloid Leukemic Cells. Blood, 2013, 122, 1255-1255.	1.4	0
179	Abstract 1182: Metformin affects breast cancer cell growth and disturbs an IGF1/insulin related gene network that correlates with breast cancer progression. Cancer Research, 2015, 75, 1182-1182.	0.9	0
180	Pharmacological Inhibition of Lck is Able to Revert Glucocorticoid Resistance in Pediatric T-ALL. Blood, 2016, 128, 838-838.	1.4	0

#	Article	IF	Citations
181	Modulation of the anti-tumor activity of VEGF blockade by metformin.. Journal of Clinical Oncology, 2017, 35, e23009-e23009.	1.6	0
182	Next generation sequencing in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD). , 2017, , .		0
183	Monitoring advanced non-small cell lung cancer (NSCLC) through plasma genotyping during systemic treatment: KRAS-mutated (m) cohort results.. Journal of Clinical Oncology, 2018, 36, e24074-e24074.	1.6	0
184	Abstract 2406: Metabolic phenotype and metastasis in patient-derived ovarian cancer xenografts. , 2018, , .		0
185	Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC.. Journal of Clinical Oncology, 2019, 37, e20612-e20612.	1.6	0
186	Genetic variability of the human CD4 V2 domain. Immunogenetics, 1996, 44, 70-72.	2.4	0